Minocycline has better CNS penetration than other tetracyclines, making it useful in treating certain neurological conditions. This superior penetration is primarily due to:

• A Minocycline is a substrate for P-glycoprotein efflux but its concentration exceeds the transporter's Km, overcoming efflux
• B Active transport by a CNS-specific organic anion transporter
• C Minocycline chelates calcium in choroid plexus epithelium, bypassing the blood-CSF barrier
• D High lipophilicity due to the 7-dimethylamino substituent and lower pKa, enabling passage across the blood-brain barrier by passive diffusion ✓

Explanation

Minocycline has a 7-dimethylamino group and an additional C9 substitution that increases its lipophilicity significantly compared to tetracycline, doxycycline, or oxytetracycline. Greater lipophilicity allows passive transcellular diffusion across the blood-brain barrier. Additionally, minocycline's lower pKa means a greater proportion is in the un-ionized form at physiological pH, further enhancing membrane permeability. This explains its use in nocardiosis, as well as proposed neuroprotective/anti-inflammatory roles (inhibiting microglial activation). Vestibular side effects (vertigo, ataxia) are the dose-limiting toxicity unique to minocycline.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.